{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T07:27:19Z","timestamp":1680247639370},"reference-count":11,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2023.2022.0295","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:33:13Z","timestamp":1677583993000},"page":"80-81","source":"Crossref","is-referenced-by-count":1,"title":["Management of Relapsed Hodgkin Lymphoma During the Second Trimester of Pregnancy: Case Report"],"prefix":"10.4274","volume":"40","author":[{"given":"Fatih","family":"Yaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan","family":"And\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"O\u011fuz Davuto\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hava","family":"\u00dcsk\u00fcdar Teke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eren","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1067\/S0002-9378(03)00537-4","article-title":"Cancer associated with obstetric delivery: results of linkage with the California Cancer Registry","volume":"189","author":"Smith","year":"2003","unstructured":"1. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California Cancer Registry. Am J Obstet Gynecol 2003;189:1128-1135.","journal-title":"Am J Obstet Gynecol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/PPO.0b013e3181a282d8","article-title":"Clinical manifestations and natural history of Hodgkin's lymphoma","volume":"15","author":"Connors","year":"2009","unstructured":"2. Connors JM. Clinical manifestations and natural history of Hodgkin's lymphoma. Cancer J 2009;15:124-128.","journal-title":"Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5603\/GP.2019.0042","article-title":"Hodgkin lymphoma in pregnancy-current management practice based on case report series","volume":"90","author":"Kroll-Balcerzak","year":"2019","unstructured":"3. Kroll-Balcerzak R, Baranska M, Gil L, Kazmierczak M, Balcerzak A, Izycki D. Hodgkin lymphoma in pregnancy-current management practice based on case report series. Ginekol Pol 2019;90:233-234.","journal-title":"Ginekol Pol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Bachanova V, Connors JM. How is Hodgkin lymphoma in pregnancy best treated? Hematology Am Soc Hematol Educ Program 2008;2008:33-34.","DOI":"10.1182\/asheducation-2008.1.33"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bjh.13327","article-title":"Management and controversies of classical Hodgkin lymphoma in pregnancy","volume":"169","author":"Eyre","year":"2015","unstructured":"5. Eyre TA, Lau IJ, Mackillop L, Collins GP. Management and controversies of classical Hodgkin lymphoma in pregnancy. Br J Haematol 2015;169:613-630.","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/ejh.12956","article-title":"The management of Hodgkin lymphomas in pregnancies","volume":"99","author":"Moshe","year":"2017","unstructured":"6. Moshe Y, Bentur OS, Lishner M, Avivi I. The management of Hodgkin lymphomas in pregnancies. Eur J Haematol 2017;99:385-391.","journal-title":"Eur J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Shmakov RG, Bellido M, Cabrera-Garcia A, Gziri MM, Halaska MJ, Ottevanger PB, Van Calsteren K, O'Laughlin A, Polushkina E, Van Dam L, Avivi I, Vandenberghe P, Woei-A-Jin FJSH, Amant F; International Network on Cancer, Infertility and Pregnancy. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol 2019;6:e551-e561.","DOI":"10.1016\/S2352-3026(19)30195-4"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/pds.4689","article-title":"Pregnancy outcomes in women exposed to cancer chemotherapy","volume":"27","author":"Danet","year":"2018","unstructured":"8. Danet C, Araujo M, Bos-Thompson MA, Portolan G, Gautier S, Vanlemmens L, Bonenfant S, Jonville-B\u00e9ra AP, Cottin J, Vial T, Bavoux F, Montastruc JL, Damase-Michel C, Benevent J, Bourgeois-Mondon I, Lacroix I. Pregnancy outcomes in women exposed to cancer chemotherapy. Pharmacoepidemiol Drug Saf 2018;27:1302-1308.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-011-1707-8","article-title":"Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy","volume":"69","author":"Mir","year":"2012","unstructured":"9. Mir O, Berrada N, Domont J, Cioffi A, Boulet B, Terrier P, Bonvalot S, Trichot C, Lokiec F, Le Cesne A. Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. Cancer Chemother Pharmacol 2012;69:357-367.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100262","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","unstructured":"10. Andrikopoulou A, Korakiti AM, Apostolidou K, Dimopoulos MA, Zagouri F. Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open 2021;6:100262.","journal-title":"ESMO Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"de Claro","year":"2012","unstructured":"11. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-5849.","journal-title":"Clin Cancer Res"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T12:31:52Z","timestamp":1678192312000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-39024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,3]]}},"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2023.2022.0295","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}